Clinical Trial Results:
A 12-week, randomized, double-blind, placebo-controlled, parallel group, multicenter study to evaluate the efficacy, safety and tolerability of darifenacin (7.5 mg o.d. with voluntary up-titration to 15 mg o.d.) in patients aged ≥ 65 years with overactive bladder
Summary
|
|
EudraCT number |
2004-002894-21 |
Trial protocol |
GB SE HU DE |
Global completion date |
22 Jun 2006
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v2(current) |
This version publication date |
01 Jun 2017
|
First version publication date |
06 Jan 2017
|
Other versions |
v1 |
Version creation reason |
|
Summary report(s) |
CDAR328A2409 |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.